Literature DB >> 8449939

Insulin-induced phosphorylation of the 46- and 52-kDa Shc proteins.

G J Pronk1, J McGlade, G Pelicci, T Pawson, J L Bos.   

Abstract

The products of the shc gene appear to be substrates for activated oncogenic tyrosine kinases, such as v-Src and v-Fps and activated tyrosine kinase receptors like the epidermal growth factor (EGF) and platelet-derived growth factor (PDGF) receptors. We investigated whether the Shc proteins are targets for the activated insulin receptor tyrosine kinase. Here we show that the 46- and 52-kDa Shc proteins are rapidly phosphorylated upon insulin receptor activation in fibroblasts expressing elevated levels of human insulin receptors. Furthermore, we observed insulin-induced association of a 23-kDa protein with the Shc proteins. These effects on Shc proteins are similar to those observed after EGF and PDGF treatment. In contrast to the observed Shc-EGF receptor association, we did not detect association between the Shc proteins and the insulin receptor. We conclude that the Shc proteins are common elements in a signal transduction pathway that is shared by EGF, PDGF, and insulin.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8449939

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  66 in total

1.  Functional analysis of H-Ryk, an atypical member of the receptor tyrosine kinase family.

Authors:  R M Katso; R B Russell; T S Ganesan
Journal:  Mol Cell Biol       Date:  1999-09       Impact factor: 4.272

2.  Regulation of insulin-stimulated tyrosine phosphorylation of Shc and Shc/Grb2 association in liver, muscle, and adipose tissue of epinephrine- and streptozotocin-treated rats.

Authors:  V Páez-Espinosa; E M Rocha; L A Velloso; M J Saad
Journal:  Endocrine       Date:  2001-04       Impact factor: 3.633

3.  Evidence for a requirement for both phospholipid and phosphotyrosine binding via the Shc phosphotyrosine-binding domain in vivo.

Authors:  K S Ravichandran; M M Zhou; J C Pratt; J E Harlan; S F Walk; S W Fesik; S J Burakoff
Journal:  Mol Cell Biol       Date:  1997-09       Impact factor: 4.272

4.  Insulin inhibits platelet-derived growth factor-induced cell proliferation.

Authors:  P Cirri; M L Taddei; P Chiarugi; F Buricchi; A Caselli; P Paoli; E Giannoni; G Camici; G Manao; G Raugei; G Ramponi
Journal:  Mol Biol Cell       Date:  2004-11-03       Impact factor: 4.138

5.  Opposite effects of the p52shc/p46shc and p66shc splicing isoforms on the EGF receptor-MAP kinase-fos signalling pathway.

Authors:  E Migliaccio; S Mele; A E Salcini; G Pelicci; K M Lai; G Superti-Furga; T Pawson; P P Di Fiore; L Lanfrancone; P G Pelicci
Journal:  EMBO J       Date:  1997-02-17       Impact factor: 11.598

6.  Multiple cytokines stimulate the binding of a common 145-kilodalton protein to Shc at the Grb2 recognition site of Shc.

Authors:  L Liu; J E Damen; R L Cutler; G Krystal
Journal:  Mol Cell Biol       Date:  1994-10       Impact factor: 4.272

7.  GRB2 and phospholipase C-gamma 1 associate with a 36- to 38-kilodalton phosphotyrosine protein after T-cell receptor stimulation.

Authors:  M Sieh; A Batzer; J Schlessinger; A Weiss
Journal:  Mol Cell Biol       Date:  1994-07       Impact factor: 4.272

8.  Insulin induces tyrosine phosphorylation of Shc and stimulates Shc/GRB2 association in insulin-sensitive tissues of the intact rat.

Authors:  V Páez-Espinosa; C R Carvalho; F Alvarez-Rojas; L Janeri; L A Velloso; A C Boschero; M J Saad
Journal:  Endocrine       Date:  1998-04       Impact factor: 3.633

9.  Dexamethasone enhances insulin-like growth factor-I effects on skeletal muscle cell proliferation. Role of specific intracellular signaling pathways.

Authors:  F Giorgino; R J Smith
Journal:  J Clin Invest       Date:  1995-09       Impact factor: 14.808

10.  The phosphotyrosine interaction domain of Shc binds an LXNPXY motif on the epidermal growth factor receptor.

Authors:  A G Batzer; P Blaikie; K Nelson; J Schlessinger; B Margolis
Journal:  Mol Cell Biol       Date:  1995-08       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.